GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Smith from ...

Stocks of major drug makers and biotech companies tumbled in the first full day of trading after Donald Trump announced that ...

GlaxoSmithKline (GB:GSK) has released an update. GlaxoSmithKline’s Blenrep combinations for treating relapsed multiple myeloma have been accepted ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £16.90. The company’s shares opened today at ...

Pharmaceuticals giant GlaxoSmithKline has told thousands of staff to turn off the NHS Covid-19 app while at work. It told them to switch off the Bluetooth contact-tracing feature at its research ...

With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...

At GlaxoSmithKline, we never lose sight of the fact that patients are at the core of what we do and that millions of lives are impacted by cancer. The patient’s voice is at the heart of our ...

GlaxoSmithKline said its key brands held their market share and continued to stay in line with the respective category performance. GlaxoSmithKline Pharmaceuticals on October 29 reported a 16 ...

Consumer goods giant Unilever says it will not sweeten its bid for the healthcare arm of GlaxoSmithKline. The maker of Marmite and PG Tips says buying GlaxoSmithKline's healthcare arm would be a ...

Oct 29 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and ...

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...